Biophytis, a biotech company, gained nearly 4% on Monday morning on the Paris Bourse after announcing the filing of a patent application in obesity, a segment it now considers a "key area" of its business.

The company, which until now has focused entirely on the treatment of age-related diseases, had announced last week its intention to position itself in this new indication with the forthcoming launch of a Phase 2 clinical trial.

This new patent application - the first issue of which is expected in 2025 - should enable the company to strengthen the position of BIO101, its main drug candidate, in the treatment of obesity in combination with GLP-1RAs, such as Novo Nordisk's Ozempic.

According to Goldman Sachs analysts, this vast market, which is currently booming, could reach some $100 billion by 2030, compared with $6 billion last year.

In detail, Biophytis' intellectual property portfolio comprises 14 patent families, including 42 issued patents and 39 patents pending, and covers the world's main regions, in particular Europe, the United States, Japan and major countries such as Brazil and China.

The patent will enable Biophytis to extend BIO101's exclusivity in this indication until 2044.

Copyright (c) 2024 All rights reserved.